Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Imagion Biosystems Limited
ABN	42 616 305 027

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Robert Romeo Proulx
Date of last notice	1 July 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	18 August 2026

<table>
<tr><td>No. of securities held prior to change</td><td>1. 4,470,749 Ordinary Shares

2. 50,000 Unlisted Performance Options, exercisable at $1.12, vesting on 1 May 2022, expiring 1 May 2027.

3. 50,000 Unlisted Performance Options, exercisable at $1.12, vesting on 1 May 2023, expiring 1 May 2028.

4. 600,000 Unlisted Class A Performance Rights (expiring 22 August 2028), vesting if the company's share price is at least $0.10 (10 cents) over 20 consecutive trading days.

5. 625,000 Options, exercisable at $0.04 (4 cents), expiring 13 December 2027.

6. 2,000,000 Unlisted Options, exercisable at $0.012 (1.2 cents), expiring 29 May 2030, comprising of:
(a) 400,000 Options vesting on submission of MagSense@ HER2 IND for Phase 2 study (or equivalent regulatory submission for another jurisdiction);
(b) 400,000 Options vesting on first patient dosed in a Phase 2 study;
(c) 1,000,000 Options vesting on completion of a Phase 2 study; and
(d) 200,000 Options vesting on submission of an IND (or like regulatory approval) for a second imaging agent.

7. 1,666,667 Listed Options, exercisable at $0.04 (4 cents), expiring 13 December 2027.

8. 3,000,000 Performance Rights comprising of:
(a) 1,000,000 Unlisted Class D Performance (expiring 24 June 2030), vesting if the company achieves a market capitalisation of $20m and maintains this for 20 consecutive trading days.
(b) 2,000,000 Unlisted Class E Performance (expiring 24 June 2030), vesting if the company achieves a market capitalisation of $30m and maintains this for 20 consecutive trading days.</td></tr>
<tr><td>Class</td><td>1) Fully Paid Ordinary Shares
2) Listed Options exercisable at $0.04 (4 cents) per Option, expiring on 13 December 2027</td></tr>
</table>

+ See chapter 19 for defined terms.

Number acquired	1) 2,083,334 Fully Paid Ordinary Shares 2) 1,041,667 Listed Options exercisable at $0.04 (4 cents) per Option, expiring on 13 December 2027
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A – securities are issued in lieu of unpaid Director's fees in the amount of $25,000 (being $0.012 per Share and nil per Listed Option), as part of directors' participation in the Placement approved under Resolution 5 at the Annual General Meeting held on 10 August 2026.

No. of securities held after change	1. 6,554,083 Ordinary Shares 2. 50,000 Unlisted Performance Options, exercisable at $1.12, vesting on 1 May 2022, expiring 1 May 2027. 3. 50,000 Unlisted Performance Options, exercisable at $1.12, vesting on 1 May 2023, expiring 1 May 2028. 4. 600,000 Unlisted Class A Performance Rights (expiring 22 August 2028), vesting if the company's share price is at least $0.10 (10 cents) over 20 consecutive trading days. 5. 625,000 Options, exercisable at $0.04 (4 cents), expiring 13 December 2027. 6. 2,000,000 Unlisted Options, exercisable at $0.012 (1.2 cents), expiring 29 May 2030, comprising of: (e) 400,000 Options vesting on submission of MagSense@ HER2 IND for Phase 2 study (or equivalent regulatory submission for another jurisdiction); (f) 400,000 Options vesting on first patient dosed in a Phase 2 study; (g) 1,000,000 Options vesting on completion of a Phase 2 study; and (h) 200,000 Options vesting on submission of an IND (or like regulatory approval) for a second imaging agent. 7. 2,708,334 Listed Options, exercisable at $0.04 (4 cents), expiring 13 December 2027. 8. 3,000,000 Performance Rights comprising of: (c) 1,000,000 Unlisted Class D Performance (expiring 24 June 2030), vesting if the company achieves a market capitalisation of $20m and maintains this for 20 consecutive trading days. (d) 2,000,000 Unlisted Class E Performance (expiring 24 June 2030), vesting if the company achieves a market capitalisation of $30m and maintains this for 20 consecutive trading days.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Shares and Free-Attaching Listed Options in lieu of unpaid director's fees, as part of director's participation in the Placement approved under Resolution 6 at the Annual General Meeting held on 10 August 2026.

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Imagion Biosystems Limited
ABN	42 616 305 027

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Brett Mitchell
Date of last notice	1 July 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	1. Mr Brett Mitchell and Mrs Michelle Mitchell <Lefthanders Super Fund A/C> (Trustee and Beneficiary) 2. Mr Brett Mitchell and Mrs Michelle Mitchell <Mitchell Spring Family A/C> (Trustee and Beneficiary)
Date of change	18 August 2026
No. of securities held prior to change	1. 5,937,575 Ordinary Shares 2. 625,000 Unlisted Performance Rights (expiring 22 August 2028), comprising of: (a) 187,500 Class A (Share price of at least $0.10 (10 cents) over 20 consecutive trading days); (b) 187,500 Class B (Market capitalisation of at least $7.5 million over 20 consecutive trading days); and (c) 250, 000 Class C (Market capitalisation of at least $12.5 million over 20 consecutive trading days).

+ See chapter 19 for defined terms.

	3. 625,000 Unlisted Performance Rights (expiring 22 August 2028), comprising of: (a) 187,500 Class A (Share price of at least $0.10 (10 cents) over 20 consecutive trading days); (b) 187,500 Class B (Market capitalisation of at least $7.5 million over 20 consecutive trading days); and (c) 250,000 Class C (Market capitalisation of at least $12.5 million over 20 consecutive trading days). 4. 1,875,000 Director Placement Options, exercisable at $0.04, expiring 13 December 2027. 5. 2,000,000 Unlisted Options, exercisable at $0.019 (1.9 cents),expiring 29 May 2028, comprising of: (a) 666,667 Options vesting on the issue date; (b) 666,667 Options vesting one year from the issue date; and (c) 666,666 Options vesting on the second anniversary of the issue date. 6. 1,666,667 Listed Options, exercisable at $0.04 (4 cents), expiring 13 December 2027. 7. 1,600,000 Performance Rights comprising of: (a) 600,000 Unlisted Class D Performance (expiring 24 June 2030), vesting if the company achieves a market capitalisation of $20m and maintains this for 20 consecutive trading days. (b) 1,000,000 Unlisted Class E Performance (expiring 24 June 2030), vesting if the company achieves a market capitalisation of $30m and maintains this for 20 consecutive trading days.
Class	1. Fully Paid Ordinary Shares 2. Listed Options exercisable at $0.04 (4 cents) per Listed Option, expiring on 13 December 2027.

+ See chapter 19 for defined terms.

Number acquired	1. 2,083,334 Fully Paid Ordinary Shares 2. 1,041,667 Listed Options exercisable at $0.04 (4 cents) per Listed Option, expiring on 13 December 2027.
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	1. 0.012 per Share 2. Nil per Listed Option

No. of securities held after change	1. 8,020,909 Ordinary Shares 2. 625,000 Unlisted Performance Rights (expiring 22 August 2028), comprising of: (a) 187,500 Class A (Share price of at least \$0.10 (10 cents) over 20 consecutive trading days); (b) 187,500 Class B (Market capitalisation of at least \$7.5 million over 20 consecutive trading days); and (c) 250, 000 Class C (Market capitalisation of at least \$12.5 million over 20 consecutive trading days). 3. 625,000 Unlisted Performance Rights (expiring 22 August 2028), comprising of: (a) 187,500 Class A (Share price of at least \$0.10 (10 cents) over 20 consecutive trading days); (b) 187,500 Class B (Market capitalisation of at least \$7.5 million over 20 consecutive trading days); and (c) 250, 000 Class C (Market capitalisation of at least \$12.5 million over 20 consecutive trading days). 4. 1,875,000 Director Placement Options, exercisable at \$0.04, expiring 13 December 2027. 5. 2,000,000 Unlisted Options, exercisable at \$0.019 (1.9 cents), expiring 29 May 2028, comprising of: (a) 666,667 Options vesting on the issue date; (b) 666,667 Options vesting one year from the issue date; and (c) 666,666 Options vesting on the second anniversary of the issue date. 6. 2,708,334 Listed Options, exercisable at \$0.04 (4 cents), expiring 13 December 2027. 7. 1,600,000 Performance Rights comprising of: (a) 600,000 Unlisted Class D Performance (expiring 24 June 2030), vesting if the company achieves a market capitalisation of \$20m and maintains this for 20 consecutive trading days. (b) 1,000,000 Unlisted Class E Performance (expiring 24 June 2030), vesting if the company achieves a market capitalisation of \$30m and maintains this for 20 consecutive trading days.

+ See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Shares and Free-Attaching Listed Options as part of director's participation in the Placement approved under Resolution 7 at the Annual General Meeting (AGM) held on 10 August 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Imagion Biosystems Limited
ABN	42 616 305 027

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Nina Webster
Date of last notice	1 July 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	JACLANI Pty Ltd <JACLANI FAMILY A/C>
Date of change	18 August 2026
No. of securities held prior to change	1. 565,211 Ordinary Shares 2. 1,600,000 Performance Rights comprising of: (a) 600,000 Unlisted Class D Performance (expiring 24 June 2030), vesting if the company achieves a market capitalisation of $20m and maintains this for 20 consecutive trading days. (b) 1,000,000 Unlisted Class E Performance (expiring 24 June 2030), vesting if the company achieves a market capitalisation of $30m and maintains this for 20 consecutive trading days.

Class	1) Fully Paid Ordinary Shares 2) Listed Options exercisable at $0.04 (4 cents) per Option, expiring on 13 December 2027
Number acquired	1) 2,083,334 Fully Paid Ordinary Shares 2) 1,041,667 Listed Options exercisable at $0.04 (4 cents) per Listed Option, expiring on 13 December 2027
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A – securities are issued in lieu of unpaid director's fees in the amount of $25,000 (being $0.012 per Share and nil per Listed Option), as part of director's participation in the Placement approved under Resolution 5 at the Annual General Meeting held on 10 August 2026.
No. of securities held after change	1. 2,648,545 Ordinary Shares 2. 1,600,000 Performance Rights comprising of: (c) 600,000 Unlisted Class D Performance (expiring 24 June 2030), vesting if the company achieves a market capitalisation of $20m and maintains this for 20 consecutive trading days. (d) 1,000,000 Unlisted Class E Performance (expiring 24 June 2030), vesting if the company achieves a market capitalisation of $30m and maintains this for 20 consecutive trading days. 3. 1,041,667 Listed Options exercisable at $0.04 (4 cents) per Option, expiring on 13 December 2027
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Shares and Free-Attaching Listed Options in lieu of unpaid director's fees, as part of director's participation in the Placement approved under Resolution 5 at the Annual General Meeting held on 10 August 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A

+ See chapter 19 for defined terms.

Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.